DOR BioPharma Company Profile

11:06 EDT 21st March 2018 | BioPortfolio

DOR BioPharma, Inc. is a biopharmaceutical company addressing life-threatening side effects of cancer and cancer treatments, serious gastrointestinal diseases and disorders, and biomedical countermeasures. Our lead product, orBec® (oral beclomethasone dipropionate), is a potent, locally-acting corticosteroid being developed for the treatment of gastrointestinal Graft-versus-Host disease (GI GVHD), a common serious complication of bone marrow transplantation for cancer, as well as other GI disorders characterized by severe inflammation. We plan to file a new drug application (NDA) with the FDA for orBec® for the treatment of gastrointestinal GVHD in the July – August timeframe of 2006
Through our BioDefense Division, we are developing biomedical countermeasures pursuant to the paradigm established by the recently enacted Project BioShield Act of 2004. Our biodefense products in development are bioengineered vaccines designed to protect against the deadly effects of ricin toxin and botulinum toxin, both of which are considered serious bioterrorism threats. Our ricin toxin vaccine, RiVaxTM, has successfully completed a Phase I clinical trial in normal volunteers. We have also initiated a botulinum toxin therapeutic development program based on rational drug design.


1101 Brickell Avenue
Suite 701 South
United States of America


Phone: 786-425-3848
Fax: 786-425-3853

News Articles [1489 Associated News Articles listed on BioPortfolio]

BioPharma Ambition 2018: Live updates from an all-island event

In between NIBRT site tours and tax workshops in Dublin Castle, Biopharma-Reporter is covering BioPharma Ambition on the Emerald Isle.

BioPharma Dive's 3 predictions for 2018 and beyond

What trends will shape the biopharma industry in 2018? BioPharma Dive's editors took a stab at predicting how the year may unfold for AI, oncology and neuroscience.

ARRAY BIOPHARMA LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Array Biopharma, Inc. To Contact The Firm

NEW YORK, NY / ACCESSWIRE / January 11, 2018 / Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Array Biopharma, Inc. ("Array Biopharma" or the "Company") (NASDAQ:...

Critical Survey: Galena Biopharma (GALE) vs. Its Peers

Galena Biopharma is one of 116 publicly-traded companies in the "Pharmaceuticals" industry, but how does it compare to its peers? We will compare Galena Biopharma to similar companies based on the str...

ACC CEO leaving to head new biopharma company

American College of Cardiology CEO Shalom “Shal” Jacobovitz is leav

#jobs #lifescience (Senior) Manager, Regulatory Operations – Biopharma

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: (Senior) Manager, Regulatory Operations – Biopharma .MA-Waltham, Direct...

New SAFE-BioPharma Standard Trust List Enables Validation of Digital Signatures in Both US and EU

A newly published SAFE-BioPharma Trust List vastly improves workflows involving sensitive and proprietary electronic documents exchanged between the US and the EU. When incorporat...

RedHill Biopharma Ltd.: RedHill Biopharma Prices Public Offering of its American Depositary Shares

TEL-AVIV, Israel and RALEIGH, N.C., 2017-11-08 15:15 CET (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) ("RedHill" or the "Company"), a specialty biopharmac...

Drugs and Medications [6 Associated Drugs and Medications listed on BioPortfolio]

Cardene® sr [PDL BioPharma, Inc.]


Recombinate [Baxter Healthcare Corporation]

RECOMBINATE [Antihemophilic Factor (Recombinant)]

Recombinate [Baxter Healthcare Corporation]

RECOMBINATE [Antihemophilic Factor (Recombinant)]

Recombinate [Baxter Healthcare Corporation]

RECOMBINATE [Antihemophilic Factor (Recombinant)]

Recombinate [Baxter Healthcare Corporation]

RECOMBINATE [Antihemophilic Factor (Recombinant)]

PubMed Articles [1 Associated PubMed Articles listed on BioPortfolio]

The positive impacts of Real-World Data on the challenges facing the evolution of biopharma.

Demand for healthcare services is unprecedented. Society is struggling to afford the cost. Pricing of biopharmaceutical products is under scrutiny, especially by payers and Health Technology Assessmen...

Clinical Trials [3 Associated Clinical Trials listed on BioPortfolio]

Single Ascending Dose Phase 1 Trial in Patients With Type 2 Diabetes

ARRY-403 is an investigational new drug being developed by Array BioPharma Inc. for treating Type 2 diabetes. The purpose of this study is to test the safety (potential side effects) and ...

A Phase 1b Study Evaluating RESTEN-MP in Subjects With Focal de Novo Stenosis

The process of re-narrowing of a coronary artery following a revascularization procedure such as angioplasty, begins at the time of the procedure. Restenosis has long been considered a ma...

Safety and Efficacy of RESTEN-MP When Used in Conjunction With a Bare Metal Stent in Coronary Arteries

The process of re-narrowing of a coronary artery following a revascularization procedure such as angioplasty, begins at the time of the procedure. Restenosis has long been considered a ma...

Companies [130 Associated Companies listed on BioPortfolio]

SAFE-BioPharma Association

SAFE-BioPharma Association ( is the non-profit association that created and manages the SAFE-BioPharma® digital identity and signature standard for the ...

Genesis Biopharma, Inc.

Genesis Biopharma, Inc. is a development-stage biotechnology company engaged primarily in the development of targeted cancer therapies. For more information on the Company, visit http://www.genesis-b...

TenX Biopharma, Inc.

TenX Biopharma, Inc., is a biopharmaceutical company focused on late stage development and commercialization of novel monoclonal antibody-based cancer therapies. TenX Biopharma acquired global rights ...

Rentschler Biopharma SE

Rentschler Biopharma SE, located in Laupheim, Germany, is a leading contract development and manufacturing organization (CDMO) for bioprocess development and manufacturing of biop...

Exostar and SAFE-BioPharma Association

SAFE-BioPharma manages the SAFE-BioPharma global digital identity and digital signatures standard, developed for and used extensively throughout the biopharmaceutical industry. LO...

More Information about "DOR BioPharma" on BioPortfolio

We have published hundreds of DOR BioPharma news stories on BioPortfolio along with dozens of DOR BioPharma Clinical Trials and PubMed Articles about DOR BioPharma for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of DOR BioPharma Companies in our database. You can also find out about relevant DOR BioPharma Drugs and Medications on this site too.

Quick Search


Relevant Topics

Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Corporate Database Quicklinks

Searches Linking to this Company Record